Trailing-twelve-month (TTM) revenue is $2.67 Billion with a year-over-year growth of (2.46%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-28 | $699,900,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-28 | $723,600,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-19 |
| Q1 FY2026Period ended 2026-03-29 | $619,800,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-28 | $630,900,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $2,674,200,000 |
Current P/S: $848,377,732 market capitalization ÷ $2,674,200,000 TTM revenue = 0.32x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T18:05:23.000Z. Latest revenue period ended 2026-06-28.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-28): $630.90M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:09:19.445Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-12-31 · USD | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222023-01-01 · USD | FY20232023-12-31 · USD |
|---|---|---|---|---|---|---|
| Cardiac Immunoassay | $267M | $267M | $243M | $256M | N/A | N/A |
| Immunoassays | $183M | $192M | $1.1B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20132013-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|---|---|
| China | N/A | $310M | N/A | N/A |
| China Segment | N/A | N/A | $325M | $335M |
| Domestic Country | $153M | N/A |
$2.67B
$2.67 Billion
(2.46%)
vs. $2.74B a year ago (TTM)
+7.14%
5 Year compound annual growth rate
1 Year
(2.46%)
3 Year
(4.55%)
5 Year
+7.14%
10 Year
+29.83%
15 Year
+21.09%
20 Year
+17.82%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.73B | ($52.70M) | (1.89%) |
| 2024 | $2.78B | ($214.90M) | (7.17%) |
| 2023 | $3.00B | ($268.20M) | (8.21%) |
| 2022 | $3.27B | +$1.57B | +92.28% |
| 2021 | $1.70B | +$36.93M | +2.22% |
| 2020 |
TTM Growth
(2.46%)
3-Year CAGR
(4.55%)
5-Year CAGR
+7.14%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T18:09:19.445Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| Molecular Diagnostic Solutions | $19M | $22M | $223M | $200M | N/A | N/A |
|---|
| Other | N/A | N/A | N/A | N/A | $303M | $483M |
|---|
| Specialized Diagnostic Solutions | $53M | $55M | $51M | $45M | N/A | N/A |
|---|
| N/A |
| EMEA Segment | N/A | $327M | $336M | $361M |
|---|
| Foreign Country | $23M | N/A | N/A | N/A |
|---|
| Latin America Segment | N/A | N/A | N/A | $253M |
|---|
| North America Segment | N/A | $1.9B | $1.6B | $1.5B |
|---|
| Other | N/A | $483M | N/A | N/A |
|---|
| $1.66B |
| +$1.13B |
| +210.66% |
| 2019 | $534.89M | +$12.61M | +2.41% |
| 2018 | $522.28M | +$244.54M | +88.05% |
| 2017 | $277.74M | +$86.14M | +44.96% |
| 2016 | $191.60M | ($4.53M) | (2.31%) |
